Arizona’s Bioscience and Life Science Directory
A guide to the state’s startups and innovators
flinn.org/bioroadmap
facebook.com/flinnfoundation azbioroadmap.bsky.social instagram.com/flinnfoundation linkedin.com/company/flinn-foundation
Introducing Arizona’s future
Welcome to the 2026 Bio Capital Conference. This directory is a snapshot of the dynamic early-stage companies shaping the future of life sciences, health tech, digital health, and BioAg across our state.
It shows the breadth of innovation and ideas that are energizing our bioscience ecosystem like never before.
The emergence of these innovators is a testament to the talent and dedication of Arizona’s entrepreneurs, researchers, and scientists who are tackling some of the most pressing health challenges of our time.
Their success is fueled by the extraordinary collaboration among Arizona’s cities, universities, government agencies, industry leaders, and community organizations. For the Flinn Foundation, this momentum is inspiring, aligning with the new Arizona’s Bioscience Roadmap and our shared vision for the future.
Mary O’Reilly, Ph.D. VICE PRESIDENT, BIOSCIENCE RESEARCH PROGRAMS FLINN FOUNDATION
The Flinn Foundation Bio Capital Conference is pleased to welcome XLR8 PBC and its current cohort of companies as featured partners in this year’s Directory.
XLR8 PBC is a program for scale-ready companies seeking the capital, experience, and validation to move to the next level. The program is focused on helping founders/CEOs tell an investment story, find experienced executives, and sign partner deals that matter most to investors. Ideal applicants have a validated product or solution, early market traction, and are seeking strategic partnerships, mentorship, and investor connections to accelerate their growth.
To learn more, please visit phoenixbiosciencecore.com/xlr8.
A.I. VALI Inc.
CONTACT: ai-vali.com, 416-786-0384, info@aivali.org
LED BY: Azar Azad, Ph.D., CEO, azar@aivali.org
FUNDING: $3.6 M (dilutive), $1.8M (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($5M extended Seed [priced] with $1.25M secured); Staff (fractional CTO, C/V level sales/marketing)
CLINICAL NEED: Early detection of cancer using medical imaging
A.I. VALI is a medtech company transforming medical imaging and workflow automation with its FDA-approved (Class I) AI platform, AIDREA. Compatible with any imaging vendor, AIDREA provides real-time diagnostic support during procedures like endoscopy and ultrasound, automatically generates patient reports (>95% accuracy), and sends them directly to EMRs for review. It instantly prepares reimbursement billing reports and streamlines workflow, as demonstrated by clinical trials showing over 20% efficiency gains and up to 20X ROI. AIDREA delivers scalable, vendor-neutral solutions that comply with regulatory standards to improve care quality, reduce expenses, boost cashflow, and drive clinical innovation across a range of clinical applications and imaging modalities.
Hexoskin
CONTACT: hexoskin.com, 888-887-2044, contact@hexoskin.com
LED BY: Pierre-Alexandre Fournier, CEO, fournier@hexoskin.com
FUNDING: $8M (dilutive)
SEEKING: Non-dilutive or dilutive funding (upcoming Series A [TBD])
CLINICAL NEED: Clinical trials; Respiratory monitoring; Cardiac monitoring and diagnostics
Hexoskin’s mission is to automate clinical decision systems and lower the cost of medical evidence for the benefit of patients. The company received FDA 510(k) clearance for its Hexoskin medical wearables in November 2025. Hexoskin’s first non-dilutive funding came from space medicine R&D contracts (CSA/NASA) to develop wearable sensors and medical AI software for astronauts. In 2019, the company decided to focus entirely on clinical applications and was chosen by Mayo Clinic for its MedTech Accelerator program. Hexoskin is a leader in the fast-growing $3.9B clinical research digital services market with hundreds of institutional customers including pharma companies, 40plus hospitals, including Harvard, Yale, McGill, and Columbia, and NASA. Patients needing cardiac/pulmonary testing can be prescribed Hexoskin biometric shirts for continuous heart/lung monitoring.
CONTACT: neurocatch.com, 228-219-0046, dereknorsworthy@healthtechconnex.com
LED BY: Derek Norsworthy, CEO, Dereknorsworthy@healthtechconnex.com
SEEKING: Dilutive funding ($5M Seed); Mentorship (medical advisory in neurology, commercial advisory, finance); Staff (Director of Operations, Sales Manager); Support Services (distributors in the neurology space)
CLINICAL NEED: Brain health
NeuroCatch is an EEG-based medical device that assesses brain function at the point of care in just six minutes and provides an immediate Brain Vital Sign report. This enables providers of all types to make objective data-driven decisions for patient care and monitoring of neurological conditions. NeuroCatch
Paxauris
CONTACT: paxauris.com, 602-661-9310, info@paxauris.com
LED BY: Tony Dietz, Founder & President, tony.dietz@paxauris.com; John Dietz, CEO, john.dietz@paxauris.com
FUNDING: $8M (non-dilutive)
SEEKING: Dilutive funding ($1M); Staff (sales and marketing lead)
CLINICAL NEED: Hearing damage
Paxauris’s mission is to improve lives by protecting ears. The Fluid™ inflatable earplugs provide a reliable and comfortable seal against dangerous or distracting noise and against water when swimming or surfing. Our electronic hearables go further, providing transparent hearing protection while also measuring actual noise exposure in the ear at the eardrum. This is the most accurate place to make this measurement because it is inside the hearing protection and closest to the site of hearing damage. As a Phoenix startup, Paxauris has developed these innovative products with funding from the U.S. Army and Navy, the Arizona Commerce Authority, the Flinn Foundation’s Bioscience Entrepreneurship Program, and the Partnership for Economic Innovation’s WearTech Center. Adoption of our technology will help consumers, workers, first responders, and service members protect their ears from today’s worldwide epidemic of noise-induced hearing damage.
ReSuture Inc
CONTACT: resuture.com, 6197849777, info@resuture.com
LED BY: Hannah Eherenfeldt, CEO & Co-Founder, hannah@resuture.com
FUNDING: $1.1M (dilutive), $2.6M (non-dilutive)
SEEKING: Dilutive funding ($250K oversubscribed Seed)
CLINICAL NEED: Surgical Simulation
ReSuture is a medical simulation company transforming how surgical devices are developed, evaluated, and taught. The company designs anatomically accurate, synthetic human tissue models that replicate the look, feel, and behavior of real vasculature. Built from patient-specific imaging or an extensive anatomical database, ReSuture’s models can simulate pulsatile blood flow and incorporate realistic disease states such as plaque, thrombi, and aneurysms— capabilities not possible with cadavers or live animal models. Embedded sensors capture real-time data on motion, force, and technique, enabling objective measurement of device performance and surgical skill. This data-driven approach supports medical device R&D, clinician training, and surgical robotics development by providing repeatable, ethical, and clinically relevant testing environments. By combining lifelike anatomy with advanced analytics, ReSuture bridges the gap between engineering, clinical practice, and education.
Using this year’s directory
The companies featured in these pages represent more than participants in the 2026 Flinn Foundation Bio Capital Conference—they reflect the innovators building the next generation of bioscience solutions in Arizona.
Our state’s life science sector is demonstrating growing breadth and depth. More researchers are pursuing entrepreneurial paths to move innovations beyond the lab. A steady emergence of new ventures is signaling strong startup momentum. Partnerships across academia, industry, and funders are strengthening a more collaborative and connected innovation ecosystem.
I invite you to explore this directory as a map of opportunity. Invest, partner, and engage: because the next breakthrough, company, or collaboration advancing health and well-being in our state and beyond may begin with a connection made here.
Joanna Yang Yowler, Ph.D.
PROGRAM MANAGER,
TRANSLATIONAL BIOSCIENCES AND ENTREPRENEURSHIP FLINN FOUNDATION
Aces Diagnostics
CONTACT: acesdiagnostics.com, 480-235-1420
LED BY: Tammy Crawford, CEO, tcrawford@acesdiagnostics.com
FUNDING: $3.4M (dilutive)
SEEKING: Dilutive funding ($6M Series A) to support clinical validation and initial commercialization activities
CLINICAL NEED: Lyme disease
Aces Diagnostics is developing and commercializing a clinically accurate diagnostic test for Lyme disease, which is recognized as a global public health threat. After investigating multiple technologies, Aces Diagnostics has exclusively licensed the novel LymeSeek test, a multiplexed Luminex-based immunoassay that accurately (greater than 90%) detects Lyme disease in patients, including in the first two weeks after infection. This will provide health care providers with the diagnostic tool necessary to accurately diagnose Lyme disease and allow physicians to intervene early and effectively treat patients.
CONTACT: advinow.com, 480-269-4146, info@advinow.com
LED BY: James Bates, CEO, james.bates@advinow.com
FUNDING: $25M (dilutive), $3M (non-dilutive)
SEEKING: Dilutive funding ($3M Bridge)
CLINICAL NEED: Physician efficiency
AdviNOW Medical is an AI vendor that completely automates all clinical and operational aspects of the medical practice. Medical practices have found that adopting AdviNOW moves their profitability up by about 1000%.
ADVINow is a company that uses AI to solve a real problem with clear go-to-market partnerships. AdviNOW Medical
Allevalux, Inc.
CONTACT: allevalux.com, 217-979-3146, care@allevalux.com
LED BY: Co-founders Nina Sharp, Ph.D., CEO, nina.sharp@allevalux.com; Dr. Todd Schwedt, CSO, todd.schwedt@allevalux.com
SEEKING: Non-dilutive or dilutive funding (raising $500K [SAFE]); Staff (Head of Sales and Marketing)
CLINICAL NEED: Migraine; Photosensitivity
Allevalux™ is a health-tech company that developed the first practical, clinically validated therapeutic white LED lighting system designed to reduce photophobia and migraine symptoms. Migraine affects more than one billion people globally, and light sensitivity is one of its most disabling and overlooked triggers, often worsened by conventional indoor lighting. Our patent-pending Neuro-Spectral Precision Illumination™ (NSPIM™) technology optimizes light spectrum and quality while preserving high-quality white light suitable for everyday use. In clinical studies, Allevalux lighting significantly reduced visual discomfort and migraine intensity, and improved cognitive performance within minutes of exposure. The drop-in fixtures integrate seamlessly into health care and workplace settings.
Aneuvas Technologies, Inc.
CONTACT: linkedin.com/company/aneuvas-technologies, 928-814-4085, aneuvas@att.net
LED BY: Tim Becker, Ph.D., CTO, tim.becker@nau.edu; William Merritt, Ph.D., VP of R&D, wmerritt@aneuvas.com
FUNDING: $6.1M (non-dilutive)
SEEKING: Dilutive funding ($500K Angel [SAFE])
CLINICAL NEED: Cerebral aneurysm; Stroke
Aneuvas Technologies is developing novel catheter-based medical devices for the treatment of aneurysms, stroke, and other vascular defects. Established in 2013 and headquartered in Flagstaff, the company specializes in minimally invasive treatment of brain aneurysms and strokes through precise delivery via the blood vessels. ATI holds four novel patents for devices that provide better biocompatibility and post-treatment outcomes of neurological defects.
Anuncia Medical, Inc.
CONTACT: anunciamedical.com, 978-942-5600, info@anunciamedical.com
LED BY: Elsa Chi Abruzzo, CEO/President, eabruzzo@anunciamedical.com; Darryl Baker, CFO, dbaker@anunciamedical.com
FUNDING: $23.5M (dilutive), $200K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($6M+ Series A with $5M closed); Mentorship (reimbursement, health economics); Staff (Head of R&D, territory sales managers/ directors); Support Services (tooling, prototyping, testing)
CLINICAL NEED: Cerebrospinal fluid management
Anuncia develops the ReFlow® platform to keep brains flowing, delivering peace of mind in CSF management and neurocritical care, aligned with existing provider and hospital workflows and reimbursement. In the U.S., over 1 million people live with CSF disorders requiring >140,000 costly/ risky VP shunt and EVD neurosurgeries annually. ReFlow® Mini is FDA-cleared and Breakthrough Device-Designated, enabling controlled, noninvasive at-home flushing to prevent shunt catheter occlusions. Mini is paired with the CaregivAR app for patient engagement, follow-up, and recurring revenues. Next, the BDD ReFlow® EVD targets EVD occlusions in neurocritical care. ReFlow® RMS is an AI-driven monitoring system with an ultrasound wearable for intracranial pressure (ICP), CSF flow, and brain compliance.
Aqualung Therapeutics Corp.
CONTACT: aqualungtherapeutics.com, 919-410-0504, info@aqualungtherapeutics.com
LED BY: Stan Miele, President & CBO, stan@aqualungtherapeutics.com; Dr. Joe GN Garcia, CEO & Founder, skip@aqualungtherapeutics.com
FUNDING: $7.25M (dilutive), $30M (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($25M Series A2); Staff (fractional CMO, medical writing, Project Manager, VP of Clinical Operations); Support services (fractional and full-time financial)
CLINICAL NEED: Inflammation and fibrosis within Respiratory; Women’s Health; Oncology; IBD
Aqualung Therapeutics is an immunotherapeutic company that has developed a humanized monoclonal antibody (mAb) ALT100 with multiple clinical indications. ALT-100 mAb attenuates innate immunity-induced multiorgan inflammation, fibrosis and neoplasia by blocking eNAMPT/TLR-4 driven inflammatory/ fibrotic cascade. ALT-100mAb has been proven safe in a Phase 1A clinical trial in healthy human volunteers and also 15 subjects with moderate/severe Acute Respiratory Distress Syndrome (PUERTA) with AE’s being similar to that of placebo, and a mAb with a half-life of approximately 21 days. Aqualung has also created a novel Precision Medicine Platform with ALT-100mAb and biomarker/genetic assay to identify ALT-100 responders in clinical trials.
Aspiro Therapeutics
CONTACT: aspirotx.com, 760-659-0779, info@aspirotx.com
LED BY: Co-founders James Lovgren, CEO, jlovgren@aspirotx.com; Julie Ledford, Ph.D., jledford@aspirotx.com
SEEKING: Non-dilutive or dilutive funding ($3M Seed)
CLINICAL NEED: Asthma; COPD
Aspiro Therapeutics is revolutionizing treatment for obstructive lung diseases by mimicking the protective power of CC16, a natural lung protein vital for healthy breathing. The company is focused on developing advanced, diseasemodifying therapies that target the underlying mechanisms of conditions like asthma and COPD, going beyond symptom relief to alter the natural course of these diseases. The company is harnessing the protective properties of CC16 to restore lung function and prevent disease progression.
Ateleva
CONTACT: ateleva.com, 928-233-5297
LED BY: Whitney Slightham, CEO, whitney@ateleva.com; Dr. Brian Cripe, CTO, briancripemd@gmail.com
SEEKING: Non-dilutive or dilutive funding ($2.1M Seed); Mentorship (executive development, grant writing, fundraising, negotiating deals); Staff (fractional CFO, fractional CMO, part-time QMS manager, business developer and/or fractional VP of Sales)
CLINICAL NEED: Respiratory failure; Critical care pulmonology
Ateleva is a medical device company developing a minimally invasive solution to address lobar lung collapse in critically ill patients. Our technology enables targeted reinflation of collapsed lung segments using a simple, balloonbased system that integrates seamlessly into existing bronchoscopy and ICU workflows. By allowing clinicians to intervene at the lobar level rather than relying on blunt whole-lung strategies, Ateleva aims to restore oxygenation more efficiently, reduce time on mechanical ventilation, and shorten ICU length of stay. The platform is designed for rapid adoption in hospital critical care settings and has potential applications in resource-constrained and dual-use environments.
BioBolt Medical (TauTona Group)
CONTACT: tautonagroup.com/project/biobolt-surgicalstapler, 949-351-3543
LED BY: Kellen Chen, Ph.D., CEO & Co-Founder, kellenchen@bioboltmedical.com
SEEKING: Non-dilutive or dilutive funding ($500K Seed); Mentorship
CLINICAL NEED: Hernia repair
BioBolt Medical introduces a breakthrough surgical stapler technology that allows surgeons to perform procedures with greater speed, efficiency, and precision. We have developed a product that can pierce, manipulate, and fix all meshes and tissues with the speed of a stapler and the strength of a suture. Current surgical staplers only work for synthetic meshes and take about five minutes to use. However, solid meshes create better patient outcomes, but are incompatible with current staplers. Surgeons are forced to either forgo their use or instead suture, which can take an hour. Our unique and patented deployment system works for all mesh types to improve patient outcomes and reduce surgical time. The company has received input from key opinion leaders and reached design freeze of our final finished product, with hard tooling completed. We are completing final tests for 510(k) clearance.
Black Canyon Bio
CONTACT: blackcanyonbio.com, 301-979-8299, info@blackcanyonbio.com
LED BY: Ken Carter, Ph.D., Executive Chairman, ken.carter@blackcanyonbio.com; Dr. Juan Montesinos, COO, juan.montesinos@blackcanyonbio.com
FUNDING: $7.6M (dilutive)
SEEKING: Non-dilutive and dilutive funding ($25M)
CLINICAL NEED: Solid tumor cancers
Black Canyon Bio develops personalized cancer vaccines using its proprietary SNAP™ Technology platform. Founded in 2023, the company advances SNAPduo, a differentiated therapeutic vaccine combining off-the-shelf shared antigens with patient-specific neoantigens. SNAP is the only platform that functionally validates both HLA Class I and Class II neoantigens for precise tumor targeting. It features a dual-hit approach with a proprietary TLR 7/8 adjuvant, enabling immediate treatment followed by personalized therapy within 9 weeks, addressing tumors. The lead program targets HPV-associated cancers, with IND filing planned for H2 2026 and clinical trials in 2027. The platform enables expansion to virus-associated and solid tumors, including colorectal, breast, prostate, and lung cancers. Developed from tech pioneered at TGen (City of Hope) and led by experienced biotech executives, Black Canyon Bio is transforming cancer immunotherapy for solid tumors: 90% of all cancers.
BMSEED LLC
CONTACT: bmseed.com, 609-532-9744, info@bmseed.com
LED BY: Oliver Graudejus, Ph.D., Founder & CEO, oliver@bmseed.com
FUNDING: $6.15M (non-dilutive)
SEEKING: Non-dilutive and dilutive funding ($1.2M in SBIR grants, $1M from strategic partners); Support Services (marketing)
CLINICAL NEED: Brain (Injury; Alzheimer’s disease; Parkinson’s disease); Cardiac efficacy; Toxicity assessment
By replicating human physiological conditions, BMSEED helps pharmaceutical companies better assess drug candidates earlier, reduce late-stage failures, and improve the overall efficiency of drug development. More than 95% of drug candidates that enter clinical trials fail—wasting enormous amounts of time, capital, and effort. A key reason is poor predictability: drugs that appear effective in lab and pre-clinical studies often fail in humans. The root cause is a fundamental mismatch between pre-clinical research conditions and human biology. Improving clinical success rates requires fixing this gap at the pre-clinical stage.
BMSEED’s technology addresses this challenge by enabling cells in the lab to behave more like cells in humans.
Branch Therapeutics, Inc.
CONTACT: branch-tx.com, 713-487-5182, info@branch-tx.com
LED BY: Richard Austin, Ph.D., CEO & Director, austin@branch-tx.com; Jacob Lackovic, Ph.D., Director of Business Development & Operations, lackovic@branch-tx.com
FUNDING: $4M (dilutive)
SEEKING: Non-dilutive or dilutive funding (upcoming $8M–$12M Series A [Q4]); Mentorship (AI in drug development, regulatory, clinical); Support Services; Partnerships
CLINICAL NEED: Colorectal cancer; Glioblastoma; Solid tumor recurrence
Branch Therapeutics is developing first-in-class, oral, dualpathway inhibitors that prevent cancer recurrence and block tumor proliferation. With lead programs in colorectal cancer and glioblastoma, our therapies target both cancer stem cell survival and proliferative signaling, transforming breakthrough science into meaningful hope for patients.
Bio, LLC
CONTACT: cactusbioscience.com, 602-341-3718, info@cactusbioscience.com
LED BY: Douglas Lake, Ph.D., Co-founder, DLake@cactusbioscience.com; Francisca Grill, Ph.D., CSO, FGrill@cactusbioscience.com
FUNDING: $50K (dilutive); $400K (non-dilutive)
SEEKING: Non-dilutive funding ($2.5M); Support Services (FDA/USDA regulatory)
CLINICAL NEED: Valley fever
The overall goal of Cactus Bio is to develop value-based solutions for valley fever diagnostic challenges in both human and veterinary settings. Cactus Bio is an early revenue company at the Health Futures Center spun out of the research laboratories of Doug Lake at ASU and Tom Grys at Mayo Clinic, Arizona. The company is meeting the clinical need in urgent care facilities, emergency departments, and veterinary clinics for a rapid test (Velox) to aid in the diagnosis of valley fever. Lake and Grys have an extensive history with multiple previous collaborative funding (>$1.5M) in their academic labs. Currently, CSO Francisca Grill is PI on a Phase I SBIR grant to Cactus Bio with an SBIR Phase II application pending. A manufacturer is in place, and revenue is projected to increase as a QMS is implemented for our rapid test in the second quarter of 2026 to address the $50 million market for valley fever testing.
Cactus
Calviri, Inc.
CONTACT: calviri.com, 480-205-6436
LED BY: Stephen Albert Johnston, Ph.D., CEO, stephen.johnston@calviri.com
FUNDING: $25M (dilutive), $7M (non-dilutive)
SEEKING: Non-dilutive ($2M) and dilutive funding ($10M [convertible note]); Mentorship (business development); Staff (COO, business development, engineers, immunologist)
CLINICAL NEED: Cancer in humans and dogs
Calviri’s mission is to end cancer worldwide. We have developed two products to enable this — a diagnostic sensitive for stage 1 tumors and a ready-made vaccine to prevent cancer. Both products are based on marrying semiconductor photolithography with peptide chemistry to create proprietary peptide chips. The manufacturing for the chips has been established. The products will be commercialized in a stepwise plan that optimizes timely return to investors. The first product is a diagnostic for dog cancer, the second a human diagnostic for recurrence of cancer — both will be introduced in 2026. A parent company, Calviri Discovery and Invention, will spin off new companies centered on commercially validated products. Calviri’s scientists have a proven track record for successful only in class inventions – including the technology that was the basis the COVID-19 vaccine.
CellMedics
CONTACT: cellmedics.net, 877-647-4297, info@cellmedics.net
LED BY: Scott Shapiro, CEO, scott.cellmedics@live.com
FUNDING: $2M (dilutive), $640K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($10M)
CLINICAL NEED: Oncology (Solid tumors; Skin tumors); Inflammatory and autoimmune disorders; Dermatologic diseases; Metabolic and endocrine diseases; Neurologic disorders; Ophthalmic diseases; Musculoskeletal and joint disorders; Localized pain
CellMedics, Inc. has developed BIOAVAILANT®, a multipatented drug-delivery platform engineered to improve the bioavailability, safety, and patient acceptance of modern therapeutics. This advanced anhydrous transdermal, topical, and ocular system enables non-invasive delivery of small molecules and biologics, including peptides, proteins, monoclonal antibodies, immunotherapeutics, and targeted chemotherapeutics that traditionally require injections or infusions. By bypassing gastrointestinal degradation and firstpass metabolism, BIOAVAILANT® has demonstrated potential for enhanced systemic exposure, deep-tissue penetration, and improved therapeutic index in preclinical studies. The platform supports programs in oncology, immunology, metabolic, neurologic, and ophthalmic diseases, positioning CellMedics as a broad, platform-based innovator addressing major limitations in global medicine and biologics delivery.
CND Life Sciences
CONTACT: cndlifesciences.com, 480-569-2900, support@cndlifesciences.com
LED BY: Dr. Todd Levine, CMO, levine@CNDlifesciences.com; Richard Morello, CEO, RJmorello@cndlifesciences.com
FUNDING: $20M (non-dilutive)
SEEKING: Partnerships (data statisticians with an interest in biomarkers and neurodegenerative diseases to mine test data for new insights)
CLINICAL NEED: Parkinson’s and related disorders
CND Life Sciences offers cutaneous testing and biomarker services for neurodegenerative disorders. The Syn-One Test® utilizes an in-office skin biopsy procedure to provide unique pathological insights early in the disease process. CND collaborates with biopharmaceutical companies to optimize clinical trials for investigational drugs by quantifying alphasynuclein in cutaneous nerves and measuring its volume over time with assistance from the company’s NerValence™ AI-based system. The company has performed over 50,000 commercial tests to date.
Dr. Fossum’s Pet Care
CONTACT: drfossums.com, 413-367-7867, Info@drfossums.com
LED BY: Sean Ford, CEO, Sean@drfossums.com
FUNDING: $550K (dilutive), $30K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($1M [round TBD]); Mentorship (regulatory, executive development)
CLINICAL NEED: Treating of enveloped viruses
Dr. Fossum’s Pet Care is a veterinarian-founded pet wellness company focused on developing science-based, all-natural supplements and topical products for companion animals. The company’s mission is to provide high-quality, effective products with minimal side effects that support overall animal health and wellness. Their formulas are designed with veterinary expertise and are intended for use by veterinarians and pet owners alike.
Effani Agriculture, Inc.
CONTACT: effani.com, 520-349-0277
LED BY: Benjamin Renquist, Ph.D., Founder, ben.renquist@effani.com
FUNDING: $1.55M (dilutive)
SEEKING: Non-dilutive or dilutive funding ($1M Series A-2); Staff (administrative assistant, technical staff)
CLINICAL NEED: Feed efficiency
Effani Agriculture is bringing to market the first test that allows for high throughput assessment of feed efficiency. Our patented test has been validated as efficacious through trials with both university and industry partners. Our patent pending automation ensures ease of application. We are scaling up production of both the automation and test kits and are assembling our sales team and support staff. We expect our first commercial sales in 2026.
Emagine Solutions Technology
CONTACT: emaginest.com, 888-345-1115, info@emaginest.com
LED BY: Co-founders Courtney Williams, CEO, courtney.williams@emaginest.com; Jose Juarez, CTO, jose.juarez@emaginest.com
SEEKING: Non-dilutive funding; Partnerships (public-private opportunities)
CLINICAL NEED: FemTech; Maternal health
Emagine Solutions Technology is tackling the maternal health crisis with technologies to make pregnancy care safer and lower cost. The U.S. is in a maternal health crisis and is the most dangerous and expensive place to give birth. This crisis affects pregnant women, their families, our communities, and our nation as we bring forth the new generation of Americans. Emagine’s AI-driven app, The Journey Pregnancy, and our remote patient monitoring technology for clinicians, ensures more mothers live through pregnancy and postpartum recovery to see their infants grow up. Emagine’s mission is a future where maternal mortality is a relic of the past.
EnduRx Pharmaceuticals Inc
CONTACT: endurxpharm.com, 855-368-2878
LED BY: David Loynd, President & CEO, dloynd@endurxpharm.com
FUNDING: $3.5M (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($500K pre-Seed); Staff (VP of Business Development)
CLINICAL NEED: Drug delivery
EnduRx Pharmaceuticals is advancing drug delivery technology that places APIs in specific organs/tissues/cells in expectation of greater efficacy and safety, and improved patient experience during and after treatment.
Gila Diagnostics
CONTACT: giladiagnostics.com, 602-525-4507
LED BY: Jim Hauert, CEO, Jim.Hauert@Gila-Diagnostics.com
SEEKING: Non-dilutive or dilutive funding ($2.5M Seed)
CLINICAL NEED: Immune profiling
Gila Diagnostics is redefining immunoassays through its proprietary Multiplexed In-Solution Protein Array (MISPA) technology. Gila Diagnostics delivers deep immune intelligence by measuring hundreds of protein-antibody interactions in thousands of samples simultaneously, in solution, with scalability, speed, and efficiency. The company says its platform transforms how diagnostics and drug discovery are performed—enabling high-content immune profiling that traditional solid-phase immunoassays cannot achieve. Backed by five issued patents, Gila Diagnostics provides a powerful foundation for infectious disease detection, immune monitoring, and biomarker discovery— unlocking insights that were previously inaccessible, impractical, or prohibitively expensive.
Gravitrex
CONTACT: gravitrexmobility.com, 564-676-1264
LED BY: Kira Burns, CEO, kira@gravitrexmobility.com
FUNDING: $700K (dilutive), $310K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($1.5M pre-Seed round with $1M secured)
CLINICAL NEED: Physical rehabilitation; Mobility
Gravitrex improves the way patients recover after a loss of mobility. By leveraging a novel technology that supports part of a person’s weight, Gravitrex’s walking-assist device makes walking rehabilitation safer and easier for both the patient and the provider administering care. Gravitrex is an AARP Age Tech Collaborative portfolio company and has funding support from NIH’s National Institute on Aging, The University of Chicago Polsky Center, and the Arizona Wear Tech Center/Partnership for Economic Innovation. Gravitrex has a waiting list for pilot testing of its beta prototype, which is in development.
HemaSense, Inc
CONTACT: hemasense.com, 928-814-1430, contact@hemasense.com
LED BY: Nathan Friedman, CEO, nathan@hemasense.com; Ben Trapp, CTO, ben@hemasense.com
FUNDING: $630K (dilutive), $260K (non-dilutive)
SEEKING: Non-dilutive funding (raising seed round for continued product development through FDA approval); Mentorship
CLINICAL NEED: Post-procedural bleeding complications
The HemaSense system is a wearable, noninvasive monitor that detects subcutaneous blood accumulation before it becomes visible at the skin level. The initial target application is detection of access-site bleeding complications during recovery following endovascular procedures (such as heart valve repair/replacement and aortic aneurysm repair). Current detection relies on manual visual inspection by nursing staff, often leading to delayed diagnosis and costly, complex interventions. Access-site bleeding complications occur in approximately 9.5% of large-diameter catheter procedures and account for billions of dollars in direct healthcare costs annually. The HemaSense system enables earlier detection and intervention, reducing patient recovery time and overall cost of care while improving clinical outcomes. The HemaSense team is a seasoned group with a track record of bringing impactful medical devices to market.
Hypersound Medical Inc.
CONTACT: hypersoundmedical.com, 847-778-4510
LED BY: Timothy Dickman, CEO, timd@hypersoundmedical.com; Charles Jepson, CFO, charlesj@hypersoundmedical.com
FUNDING: $55K (dilutive), $525K (non-dilutive)
SEEKING: Dilutive funding ($500K Seed); Staff (engineers)
CLINICAL NEED: Chronic management
Neuroharmonix, a novel, patented medical device applied non-invasively to the surface of the body, was discovered by Bruce Towe, emeritus professor at Arizona State University. Hypersound Medical acquired the intellectual property and began animal testing to prove the science nearly three years ago. The device uses a specific radio frequency (below the microwave band width) with a multi antennae system controlled by a radiofrequency circuit board. Depending on the settings, the interaction of the signals can block or stimulate nerve cells to stop pain. The company received an SBIR grant from the National Science Foundation and then successfully proved the science in animal testing.
IMMUN OSHIELD THERAPEUTICS
ImmunoShield Therapeutics
CONTACT: immunoshieldtherapeutics.com, 480-788-6717, info@immunoshieldtherapeutics.com
LED BY: Matthew Becker, Ph.D., CEO, matt.becker@immunoshieldtherapeutics.com
FUNDING: $2.6M (non-dilutive)
SEEKING: Dilutive funding ($500K pre-Seed [SAFE])
CLINICAL NEED: Cell therapies for type 1 diabetes
ImmunoShield Therapeutics is building technology to solve one of the biggest barriers in the next frontier of medicine — enabling allogeneic cell therapies without the need for chronic immune suppression. Our platform combines automated, high-throughput biomanufacturing with a novel immune protection strategy to create truly scalable, durable cell therapies. When fully deployed, ImmunoShield’s technology will unlock the full potential of regenerative medicine. Our goal is to bring curative therapies, not lifelong treatments, to millions of patients with chronic diseases such as insulin-dependent diabetes.
King Therapeutics
CONTACT: king-tx.com, 602-516-2199
LED BY: Co-founders David Richardson, drichardson@king-tx.com; Isaiah Slemons, islemons@king-tx.com
FUNDING: $310k (dilutive)
SEEKING: Dilutive funding ($2M); Staff (fractional CMO)
CLINICAL NEED: Novel immunotherapy
King Therapeutics is activating macrophages against cancer cells instead of using T-cells. Macrophages are better at infiltrating solid tumors, less likely to cause serious side effects, and they recruit other immune cells. King Therapeutic’s BiMa (BiSpecific Monocyte Activator) platform is tunable to various cancers, providing opportunity for development. The company is seeking funds to manufacture initial compounds and test efficacy and safety.
LifeSpan Digital Health
CONTACT: lifespandh1.com, 678-767-0808
LED BY: Jeffrey Cary, CEO; Lynn Andrews, CPO
FUNDING: $250K (dilutive), $100K (non-dilutive)
SEEKING: Dilutive funding ($3M)
CLINICAL NEED: Physician wellness; Burnout prevention
LifeSpan Digital Health, Inc. is an Arizona-based company founded in 2024 focused on transforming physician and healthcare worker wellness through predictive AI, wearable technology, and evidence-based behavioral insights. Its platform integrates biometric data, machine-learning risk modeling, and workflow-aware interventions to identify early signs of burnout, fatigue, and cognitive overload. LifeSpan delivers personalized support to clinicians, program-level analytics to training institutions, and organization-wide insights for health system leadership. By combining bottomup individual tools with top-down institutional strategies, the company supports healthier work environments, improves retention, and strengthens patient care.
The Lillian Project
CONTACT: thelillianproject.ai, 310-570-8508
LED BY: Co-founders Jeremy Jordan, CEO, jeremy@thelillianproject.ai; Ben Smith, Ph.D., CTO, benksmith.2005@gmail.com
SEEKING: Non-dilutive or dilutive funding ($1M Seed); Mentorship, Staff, or Support Services (grant writing, regulatory, website development, legal, cyber security, patents, fundraising)
CLINICAL NEED: Dyslexia screening, treatment, and early intervention
The Lillian Project was founded by Jeremy Jordan and Ben Smith, two leaders united by a mission to change outcomes for children with dyslexia. Jeremy, a father of a dyslexic learner, brings the vision, business leadership, and commitment to education equity, driven by the belief that early intervention can change a child’s life. Ben, who is dyslexic himself and a father to dyslexic children, leads technical development, translating advanced AI into scalable school solutions. Together, they built The Lillian Project to solve a critical gap. TLP is an emotionally intelligent, AI-powered platform that unifies screening, personalized intervention, and progress monitoring using proprietary, research-backed IP to restore confidence, unlock potential, and change futures through early, effective support.
Macula Vision Systems
CONTACT: macula-vision.com, 857-919-0696
LED BY: Oleg Gusyatin, CEO, oleg@macula-vision.com
FUNDING: $1.7M (dilutive), $500K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($3M for commercialization expansion); Mentorship (M&A advisory); Staff (commercial development, scientific marketing, tech support)
CLINICAL NEED: Infectious disease (Sepsis; Tuberculosis; Parasitology)
Macula Vision Systems is building a solution for full automation and interpretation of clinical microscopy addressing critical labor shortages, pressure to cut costs, and the need for accurate timely clinical information in community, rural, and urban clinical laboratories. Macula’s automation has a positive impact on efficiency and quality of diagnostic results and workflow, as it will be 3000x more sensitive, interpret samples 20x faster, 20x more accurately, and 10x cheaper than today’s laboratory technician. Macula’s first solution for clinical microbiology smear sample interpretation has been validated in New England’s leading academic children’s hospital and is addressing a global market of $2.2 billion.
MBCA Inc.
CONTACT: mbcaconsulting.com, 520-665-9081, info@mbcaconsulting.com
LED BY: Melita Ball, Founder & CEO, mball@mbcaconsulting.com
FUNDING: $200K (dilutive)
SEEKING: Dilutive funding ($2M Seed [convertible notes] with $200K secured) to launch IntelaSolve eQMS; Mentorship (B2B RegTech SaaS Advisor, MedTech SaaS GTM Strategist, capital formation); Staff (fractional or contract technical resources, fractional GTM support); Advisory Board members
CLINICAL NEED: Internal QMS and regulatory compliance for MedTech, Medical Device, and Diagnostics companies
MBCA Inc. is behind IntelaSolve eQMS, a clinically agnostic, cloud-based Quality Management System built for medical device and diagnostics companies. IntelaSolve addresses a critical market gap and enables organizations to design, implement, and maintain systems that support product development to commercialization and beyond. Proxi, an agentic AI layer built into IntelaSolve, helps teams navigate, generate, and maintain QMS artifacts and workflows with greater speed, consistency, and inspection readiness while reducing admin burden and improving traceability and execution. The platform is informed by 35-plus years of industry experience from founder & CEO Melita Ball.
MedAccelera Management
CONTACT: medaccelera.com, 818-355-3343, info@medaccelera.com
LED BY: Pedro Medrano, CEO, pedro@medaccelera.com
SEEKING: Non-dilutive funding ($100K–$250K)
CLINICAL NEED: Dermatology; Medical imaging; Ophthalmology
MedAccelera Management is a medical device-focused venture studio managed by industry veterans with extensive operational experience. Our mission is to create ventures that offer significant market opportunities by addressing large, unmet clinical needs through the identification and development of breakthrough medical device technologies. We are especially interested in addressing unmet clinical needs in the dermatology, medical imaging and ophthalmology sectors. Our approach is to perform extensive market, clinical and regulatory due diligence to deliver operational strategies that maximize value creation and risk mitigation. A key goal of MedAccelera Management is to function as a bridge between university innovation and institutional investors.
CONTACT: mendbridgebiotech.com, 480-309-9231, info@mendbridgebiotech.com
LED BY: Ozzy Ledezma, Co-Founder & President, ozzy.ledezma@mendbridgebiotech.com
SEEKING: Non-dilutive or dilutive funding for technical validation, prototype development, and early regulatory strategy; Mentorship (regulatory, reimbursement, clinical trial design, IP positioning, executive development, grant writing); Partnerships (wound care)
CLINICAL NEED: Diabetic foot ulcers; Venous leg ulcers; Pressure injuries; Complex non-healing wounds
MendBridge is an early-stage medical device company developing a next-generation smart wound dressing for chronic, non-healing wounds, beginning with diabetic foot ulcers. Our platform integrates proprietary regenerative and bioactive technologies designed to actively stimulate tissue repair while reducing infection risk. Unlike traditional passive dressings, our solution enhances cellular migration and angiogenesis through localized stimulation generated by natural body movement, without requiring external power. We aim to reduce amputations, hospitalizations, and long-term healthcare costs by providing an accessible, noninvasive solution for patients with complex wounds.
MendBridge
Metfora Diagnostics
CONTACT: metfora.com, 508-400-5307, info@metfora.com
LED BY: Martin Fuchs, CEO, martin.fuchs@metfora.com; Debrah Thompson, Ph.D., CSO, dthompson@metfora.com
FUNDING: $975K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($2M)
CLINICAL NEED: COPD; ILD; PAH/PH; Asthma
Metfora Diagnostics is a spinout from the University of Arizona based on research performed in the laboratories of professors Ruslan Rafikov and Olga Rafikova. Metfora is developing a blood test that can diagnose four different lung diseases (COPD, ILD, Pulmonary Hypertension and Asthma) from a single blood draw. The test addresses the challenges providers face to accurately diagnose patients presenting with fatigue and shortness of breath. With the exception of lung cancer, blood tests for lung disease do not exist. The test addresses a $10.1 billion market opportunity.
Microvascular Therapeutics
CONTACT: mvtpharma.com, 520-730-3264
LED BY: Emmanuelle Meuillet, Ph.D., COO/CSO, e.meuillet@mvtpharma.com; Thom Tulip, CBO, t.tulip@mvtpharma.com
FUNDING: $4.8M (dilutive), $11.9M (non-dilutive)
SEEKING: Dilutive funding ($8M)
CLINICAL NEED: Cardiovascular (Deep vein thrombosis; Pulmonary emboli; Heart attack; MI); Oncology (Brain; Solid tumors); Alzheimer’s disease
Microvascular Therapeutics (MVT) is a biotechnology company specializing in the development of microbubble and nanobubble products that will unlock the diagnostic and therapeutic potential of ultrasound. MVT has invented a new ultrasound contrast agent, CardiSon (MVT-100), which promises to be the best combination of image quality, storage/handling, and side-effect profile of any ultrasound contrast agent on the market. CardiSon has finished a positive Phase 1/2 clinical testing for echocardiography — a $720 million global market in 2024, with global ultrasound contrast sales expected to reach $2 billion by 2030. The asset is phase 3 ready with projected approval in Q2-2027. CardiSon is a near-term revenue opportunity and a platform technology that positions MVT to propel a pipeline of disruptive therapeutic products into the market that will have a broad impact across a spectrum of medicines, with massive market potentials.
MiiCare
CONTACT: miicare.com, contact@miicare.com
LED BY: Co-founders Kelvin Summoogum, CEO, kelvin@miicare.com; John Wall, Head of Engineering, john@miicare.com
FUNDING: $3M (dilutive), $3M (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($6M Seed+/preSeries A [priced]); Mentorship, Staff, or Support Services (impact-driven sales, GTM specialists, grant support, resale, scaling)
CLINICAL NEED: Aging; Hospital at home; Decentralized clinical trials; Diabetes; Dementia; Frailty; Falls; UTI
With the backing of AARP, Mayo Clinic, Samsung, and more, MiiCare has helped prevent 77% of hospital readmissions and extend health-span for thousands of older adults at home, across 50-plus healthcare providers. The wholehealth platform collects and analyzes over 75 in-home, ambient, behavioral datatypes, generating self-care assessments and preventative care plan support for care managers. Then, its conversational AI companion, Monica, engages proactively by voice every day in a social experience that nudges self-care behaviors, cutting care delivery costs and boosting outcomes.
MiiHealth AI
CONTACT: miihealth.ai, 480-369-8645, hello@miihealth.ai
LED BY: Jacob Lester, Co-Founder, Jacob@miihealth.ai; Kelvin, CEO & Chair, kelvin@miihealth.ai
FUNDING: $550K (dilutive), $40K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($1.5M Institutional or Angel with $550K secured); Partnerships (health systems and small clinics)
CLINICAL NEED: Provider burnout; Patient intake; Cardiology; Orthopedics
MiiHealth AI is building DAINA, an autonomous conversational AI medical assistant that completes patient intake before a patient ever arrives at the health system. DAINA proactively calls or texts patients to ask the same intake questions providers typically ask at the start of a visit, regardless of specialty, capturing the reason for visit, symptoms, history, specialty specific information, and other required details. She conducts these conversations in the patient’s language of choice, then contextualizes the responses into a structured clinical note with key insights and red flags for clinician review. That note is implemented into the EHR (electronic health record) so the care team can review, walk in prepared, and focus on clinical decisionmaking and patient connection rather than documentation and repetitive questioning. Based in Phoenix, MiiHealth AI is actively piloting with Mayo Clinic Arizona and others.
Mindsigns Health™
CONTACT: mindsignshealth.com, 551-252-8988, information@mindsignshealth.com
LED BY: Michel Birnbaum, Co-Founder & CEO michelbirnbaum@mindsignshealth.com; Kevin Loh, Digital Marketing Manager, kevin.l@mindsignshealth.com
FUNDING: $1M (dilutive), $350K (non-dilutive)
SEEKING: Non-dilutive ($500K) and dilutive funding ($3M); Mentorship (hospitals and specialty centers GTM), Staff (Chief of Staff, business development, finance, algorithm & data science, software engineering, database management); Support Services (regulatory, IP)
CLINICAL NEED: Neuropsychiatry indications (Mild traumatic injuries; Concussions; Cognitive impairment)
Mindsigns Health™ is a clinically validated neuropsychiatry platform. From seizure detection to negative symptoms and cognitive monitoring, we deliver objective and scalable solutions, benefiting both patients and healthcare providers. Our mission is to help patients with neurological and psychiatric disorders from hospital to home. Our platform combines analytics engines that power a new standard of precision in monitoring and managing brain conditions. NeuroBrowser™: Enterprise EEG SaaS for hospitals and clinics. GenMind™: Remote monitoring for improved access, quality, and delivery of mental health care. Mindsigns Health™ is HIPAA, GDPR and PDPA compliant.
NuvOx Therapeutics Inc.
CONTACT: nuvoxtherapeutics.com, 520-624-6688, info@nuvoxpharma.com
LED BY: Rong Wang, President & CEO, rwang@nuvoxpharma.com
FUNDING: $19.7M (dilutive), $15.5M (non-dilutive)
SEEKING: Non-dilutive or dilutive funding for clinical research
CLINICAL NEED: Oncology; Stroke; Respiratory distress
NuvOx Therapeutics develops an oxygen therapeutic platform that eliminates tissue hypoxia, the root cause of many injuries, deaths, and resistance to standard treatment. Our applications are extremely broad, with two Phase IIb programs: oncology (enrollment and treatment already completed), and stroke. In addition, we have a Phase Ib respiratory program with partial completion and positive results. In addition, the company has a solid pre-clinical pipeline.
The Pause Technology
CONTACT: thepause.ai, 480-882-8069 or 602-930-8197
LED BY: Co-founders Susan Sly, CEO, susan.sly@thepause.ai; Mia Chorney, DNP, CMO, mia.chorney@thepause.ai
SEEKING: Non-dilutive or dilutive funding (upcoming Seed [Q4]); Mentorship (grant writing)
CLINICAL NEED: Women’s health
The Pause Technology is a female founded digital health company focused on redefining how menopause and midlife health are understood and supported. Through its AI powered platform and thePause® app, the company helps women better understand their symptoms, identify their stage of menopause, and make informed decisions about sleep, nutrition, and movement to improve quality of life. Founded by Susan Sly and Mia Chorney, The Pause Technology blends clinical expertise with practical, easy to use technology. The platform delivers personalized insights, evidence based education, and ongoing support designed for real life, not perfection. By addressing an overlooked stage of women’s health, The Pause Technology is working to normalize perimenopause and menopause, close care gaps, and help women feel confident and supported through midlife and beyond.
Prata Health
CONTACT: pratahealth.com, 480-404-4737, info@pratahealth.com
LED BY: Bianca Fabbo, MSN-ed/RN, President & Founder, bianca@pratahealth.com
SEEKING: Staff (Registered Nurses, Certified Nursing Assistants)
CLINICAL NEED: On-demand medical care and coordination
Prata Health is a luxury concierge nursing company providing 24/7 registered-nurse–led care for individuals and families. Our core services include aging in place, healthcare navigation, and skilled nursing care, all delivered through highly personalized, nurse-directed care plans. We focus on seamless coordination, advocacy, and hands-on clinical support, treating every client as part of the Prata Health family and providing care with the same attention, respect, and compassion we would offer our own.
Precision Epigenomics
CONTACT: precision-epigenomics.com, 520-372-7522, support@precision-epigenomics.com
LED BY: Mark A. Nelson, Ph.D., CEO, manelson@precision-epigenomics.com; Dr. Richard Bernert, COO, rbernert@precision-epigenomics.com
FUNDING: $1.9M (dilutive), $2M+ (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($2M [convertible note])
CLINICAL NEED: Cancer diagnosis
EPISEEK™ detects the top 10 deadliest cancers from one blood draw, including bladder, liver, pancreas and endometrial. Compared to the first-mover competitor, it’s faster, more affordable, scalable, and comparable, if not superior, in performance. Current test revenue is from B2C and B2B2C revenue models. Licensing agreements are being implemented to scale globally with new tests to be launched during the next five years.
CONTACT: precisionmedorthocorp.com, 480-322-9497
LED BY: Cameron Jeffers, CEO, cjeffers2014@gmail.com; Gabriella Alessio, President, gfalessio@gmail.com
SEEKING: Non-dilutive funding ($500K); Mentorship (executive development)
CLINICAL NEED: Kyphosis/scoliosis; Growth modulation in pediatric orthopedics
Precision MedOrtho focuses on advancing growth modulation solutions in pediatric orthopedics through the development of novel, precision-engineered orthopedic implants. We address unmet clinical needs in children with limb deformities and neuromuscular conditions by designing implants that enable controlled, predictable correction while minimizing surgical burden and long-term complications. Our approach integrates biomechanical insight, translational research, and modern manufacturing techniques to improve safety, efficacy, and adaptability across a range of skeletal pathologies. By prioritizing minimally invasive designs and growth-friendly mechanics and through close collaboration with clinicians and researchers, our technologies aim to reduce repeat surgeries, improve functional outcomes, and enhance quality of life for pediatric patients.
Precision MedOrtho
Prickly Pear Health
CONTACT: pricklypear.io
LED BY: Imen Clark, Founder & CEO, imen@pricklypear.io
FUNDING: $500K+ (dilutive), $50K non-dilutive
SEEKING: Non-dilutive funding ($600K pre-Seed); Mentorship and Support Services (regulatory, grant writing)
CLINICAL NEED: FemTech; Brain health; Women’s health
Prickly Pear Health is a voice-first AI company advancing women’s brain health across key life and hormonal transitions. Women experience higher rates of many brainrelated conditions, including Alzheimer’s disease, depression, anxiety, migraine, and multiple sclerosis; burdens that often intensify during periods of hormonal change, caregiving, and sustained cognitive and emotional load. Prickly Pear Health addresses a critical gap in how women’s brain health is understood by capturing signals traditional systems miss. The platform combines voice journaling with wearable, behavioral, and lifestyle data to reflect how women are functioning day to day. By listening not only to what women say, but how they say it, Prickly Pear surfaces patterns related to cognition, mood, sleep, energy, and resilience, transforming scattered signals into structured, personalized insights.
Radiation Detection and Imaging (RDI) Technologies
CONTACT: radiationimaging.com, 602-842-4901, contact@radiationimaging.com
LED BY: Evgeny Galyaev, Ph.D., CEO, egalyaev@radiationimaging.com; Pablo Camacho, CTO, pablo.camacho@radiationimaging.com
FUNDING: $1.7M (non-dilutive)
SEEKING: Funding ($1.5M–$3M)
CLINICAL NEED: Cancer radiotherapy
RDI Technologies specializes in advanced radiation measurement and quality assurance solutions for modern cancer radiotherapy. RDI develops state-of-the-art detector systems and data acquisition technologies to improve the precision, safety and efficiency of treatments including proton therapy and FLASH radiation therapy. A patented, high-resolution imaging technology enables real-time, NIST-traceable dosimetry with unmatched accuracy, and goes beyond specific radiotherapy applications. Strong partnerships with Mayo Clinic and MD Anderson position RDI at the forefront of radiotherapy innovation. The company cites its scalable business model, encompassing hardware, software, and service contracts, ensuring long-term sustainability and growth.
Reference Medicine
CONTACT: ReferenceMedicine.com, 602-376-0618, hello@ReferenceMedicine.com
LED BY: Inga Rose, Founder & CEO, inga@ReferenceMedicine.com; Abby Murphy, Director of Strategy & Operations, abby@ReferenceMedicine.com
SEEKING: Staff (clinical research professionals, oncology specialists, full or part-time laboratory technicians)
CLINICAL NEED: Oncology biospecimen services
Reference Medicine specializes in human biospecimens for cancer research, providing FFPE tissue, fresh/frozen samples, matched sets, and clinical remnant material to diagnostic developers, CROs, and biopharma teams worldwide. Whether you need annotated tumor samples, cfDNA with known variants, or NGS-ready material, the company’s mission is to make biospecimen procurement the easiest part of a project. At Reference Medicine, we apply the same scientific rigor and continuous innovation seen in oncology diagnostics and therapeutics to the world of specimen sourcing. Our transparent, reliable approach ensures rapid turnaround, consistent quality, and fair pricing because sample access shouldn’t slow down science.
Robust Diagnostics, LLC
CONTACT: robustdx.com, 480-299-9779, info@robustdx.com
LED BY: Chris Diehnelt, Ph.D., CEO, cdiehnelt@robustdx.com
FUNDING: $180K (dilutive), $750K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($2M Seed) to advance to LDT
CLINICAL NEED: Multiple sclerosis
Robust Diagnostics is developing the world’s first blood test for early detection of multiple sclerosis.
Saccadous, Inc.
CONTACT: www.saccadous.com, 314-322-8616, x@saccadous.com
LED BY: Michael S. Anderson, CEO, manderson@saccadous.com; Justin McBride, Marketing Operations, jmcbride@saccadous.com
FUNDING: $1M (dilutive)
SEEKING: Dilutive funding ($4M)
CLINICAL NEED: Parkinson’s disease; Other neuromotor disorders
Saccadous is developing SaccadeDX™, the first objective test for diagnosing Parkinson’s disease by analyzing eye movements. Currently, diagnosis relies on subjective assessments and irreversible motor symptoms, leading to a misdiagnosis rate of up to 60%. This delay prevents early intervention when treatment is most effective, resulting in significant health and economic consequences. SaccadeDX™ leverages a non-invasive VR headset to capture complex eye movements in 10 minutes. Our proprietary algorithm analyzes these patterns to distinguish Parkinson’s from healthy controls and other related neurological disorders. In a Phase II study (2022), the algorithm achieved 91% accuracy in matching expert neurologists’ diagnoses. Funding will support regulatory clearance. Saccadous is partnering with local clinical sites and expanding operations in Scottsdale.
Serenity Neurotechnologies LLC
CONTACT: se\renityneurotech.com, 480-466-3309
LED BY: Co-founders Jit Muthuswamy, Ph.D., CEO, jit@serenityneurotech.com; Dev Ramachandran, CFO, dev@serenityneurotech.com
FUNDING: $52.5K (dilutive), $4M (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($3M–$5M); Staff (part-time electrical or biomedical engineers), Support Services (clinical advisors)
CLINICAL NEED: Migraine
Serenity Neurotechnologies LLC is focused on developing a solution for chronic migraine using neuromodulation technologies invented in the research laboratories of Jit Muthuswamy and Bruce Towe at Arizona State University. A significant fraction of migraine patients suffers debilitating pain that current medications fail to relieve. That’s why we offer an effective at-home therapy designed to reduce pain and help patients regain control and thrive. We are developing a wireless, implantable neurostimulator (WINS) for abortive treatment of chronic migraine at home. Our solution will be minimally invasive and implanted in an outpatient procedure by a neurologist or a neurosurgeon. Treatment is subsequently administered by the patient as needed at home. The company envisions its solutions to be broadly applicable to other headache disorders and neurological dysfunctions in the future.
T-ceptor Bio
CONTACT: tceptorbio.com, 484-883-8947
LED BY: Maran Sprouse, Ph.D., CEO, Maran.Sprouse@TceptorBio.com; Zach Dobson, Ph.D., CTO, Zach.Dobson@TceptorBio.com
SEEKING: Non-dilutive or dilutive funding (upcoming Seed [TBD])
CLINICAL NEED: Autoimmune diseases, starting with Type 1 Diabetes
T-ceptor Bio is a preclinical biotech company developing a new class of tissue-targeted immunotherapies designed to restore immune tolerance without systemic immunosuppression. Our platform, Fab-Checkpoint Agonists (Fab-CKAs), combines disease-relevant tissue targeting with localized immune checkpoint signaling to suppress pathogenic immune responses only at sites of inflammation. Our lead programs focus on autoimmune diseases with high unmet need, beginning with type 1 diabetes. By concentrating immunomodulation where disease occurs, our approach aims to improve efficacy while reducing safety risks associated with systemic immune suppression. T-ceptor Bio operates as a capital-efficient, virtual biotech, leveraging strategic academic and CRO partnerships to advance candidates through preclinical development. Our team brings deep expertise in protein engineering, immunology, and translational biology.
UGenome AI
CONTACT: ugenome.io, 818-398-8121
LED BY: Zachary S. Brooks, Ph.D., Founder & CEO, zachbrooks@ugenome.io; Marco Schito, Ph.D., Scientific & Business Director, marcoschito@ugenome.io
FUNDING: $150K (dilutive), $25K (non-dilutive)
SEEKING: Non-dilutive or dilutive funding ($5M Series A); Mentorship (regulatory); Staff (sales); Support Services; Partnerships
CLINICAL NEED: Rare disease diagnostics; Women’s health (cardiology); Cancer diagnostics
UGenome AI makes genomic medicine personal and accessible for everyone by producing genomic and multi-omic tools on the cloud to provide information for researchers and clinicians to improve treatment options for their patients.
Valley Fever Solutions
CONTACT: ValleyFeverSolutions.com, 650-454-4126, info@valleyfeversolutions.com
LED BY: David Larwood, Ph.D., CEO, DavidL@ValleyFeverSolutions.com
FUNDING: $1M (dilutive), $7.8M (non-dilutive)
SEEKING: Non-dilutive funding or dilutive funding ($12M) to secure key data on drug effectiveness; Mentorship; Staff; Support Services
CLINICAL NEED: Valley fever; Fungal diseases
Valley Fever Solutions is dedicated to getting FDA approval for a drug to eradicate valley fever. The CEO co-invented two commercial drugs including the shell of the mRNA COVID vaccines. He managed and improved manufacturing of our drug at large scale. Our team has decades of experience in biotech and looks forward to saving the lives of humans and pets.
CONTACT: vivamed.com, 480-688-2657, info@vivamed.com
LED BY: Kendric Speagle, CEO, kbspeagle@vivamed.com; Kate Fassett, CDO, kfassett@vivamed.com
SEEKING: Dilutive funding ($260M institutional capital, $20M Series A) for different pipelines of drug assets and technology
CLINICAL NEED: Repurposed drugs
VivaMed is focused on developing drug assets that meet an unmet global need. The company has fostered and developed two active pipelines of development. The first is in partnership with research-based universities to license drug assets nearing a clinical stage of development, form the capital and research plans to take the asset through Phase II clinical trials for a viable exit. The second pipeline (Pharma R1) focuses on developing and validating the scientific hypotheses generated via our AI platforms for repurposed drug assets where significant improvements can be made to support new foundation IP. VivaMed BioPharma
VYSRE, Inc
CONTACT: vysre.com, 714-654-7770, info@vysre.com
LED BY: Dr. Chung Trinh, CEO, chung@vysre.com
SEEKING: Non-dilutive or dilutive funding ($1.5M Seed) for validation and manufacturing; Mentorship (executive development, company strategy, regulatory); Staff (board, executives)
CLINICAL NEED: Mental health (Depression; Anxiety; PTSD); Dementia; Post-stroke recovery
VYSRE is medtech company dedicated to putting mental health care into the hands of individuals, giving patients greater ownership of their healing process. Our closed-loop surveillance and intervention technology allows individuals to self-administer treatments in the comfort of their home in-between visits to their physicians. This creates a more effective and sustainable continuity of care strategy to mitigate relapse of disease. VYSRE’s noninvasive wearable technology leverages AI-guided EEG surveillance paired with patent-pending brain activating stimulation which is packaged into a user-friendly form factor. Our strategy to scale and commercialization involves adopting both a consumer and regulatory path to address the more than 60 million people in the U.S. suffering from mental illness — many of whom are not receiving adequate care.
CONTACT: ZelosDX.com, 520-907-326
LED BY: Alie Buckmire, Ph.D., CEO, ABukmire@zelosdx.com; Marie Wesselhoft, Co-Founder & Board Member, mwesselhoft@zelosdx.com
FUNDING: $2.7M (dilutive), $1M (non-dilutive)
SEEKING: Non-dilutive funding ($350K); Dilutive funding ($250K); Mentorship (strategic partnerships, fundraising); Staff (fractional or full-time CSO/CTO)
CLINICAL NEED: Alzheimer’s disease
ZelosDx has developed WINDOW INTO THE BRAIN™, a disease-agnostic, temporally specific blood test platform that detects neurological disease by analyzing phagocytes— immune cells that actively traffic debris from the brain. This brain debris provides evidence of damage and insight into neuroinflammation, disease activity, and treatment response. Key advantages include: temporal specificity, reflecting recent and active neurodegeneration; higher signal in earlystage or low-concentration disease states; compatibility with flow cytometry, ELISA, and Western blot; utility across human and animal research models; and complementary results with serum/plasma biomarkers. ZelosDx offers a unique technology platform that provides new insights into neurodegenerative diseases. ZelosDX
All information contained in this Directory is self-reported by participating companies. The Flinn Foundation did not independently verify the accuracy or completeness of the information, and inclusion in this Directory does not constitute an endorsement by the Foundation.
Company Index
flinn.org/bioroadmap
facebook.com/flinnfoundation
azbioroadmap.bsky.social instagram.com/flinnfoundation linkedin.com/company/flinn-foundation